The consumer health company also disclosed its CEO’s departure, following its CFO replacement earlier this year, and appointed an interim chief executive. Preliminary second-quarter 2025 results show ...

The 12-month price targets, analyzed by analysts, offer insights with an average target of $23.58, a high estimate of $25.00, ...

Kenvue, the Johnson & Johnson spinoff that makes Tylenol and Benadryl, named director Kirk Perry as interim chief executive ...

Kenvue (KUVE) has named Kirk Perry, a current director, as its interim CEO, effective immediately. Concurrently, Thibaut ...

With activist investor Starboard Value holding a seat on Kenvue’s board of directors, the consumer healthcare company is ...

Kenvue says that CEO Thibaut Mongon is departing as the maker of Listerine and Band-Aid brands continues with a strategic ...

Kenvue’s board of directors are considering ‘a broad range of potential alternatives’ and are hunting for a permanent ...

Kenvue CEO Thibaut Mongon has stepped down as the company’s chief executive and departed its board of directors. The CEO of Tylenol maker Kenvue ( KVUE) has left the company as part of an internal ...

Editor’s Note: Self care segment revenue growth updated Consumer health company Kenvue Inc. (NYSE:KVUE) on Thursday reported first-quarter 2025 sales of $3.74 billion, beating the consensus of ...

Separately, Kenvue announced the appointment of Amit Banati as the Company's Chief Financial Officer, effective May 12, 2025. He will succeed Paul Ruh, who will remain with the Company for a brief ...

The company is working to reduce tariffs’ financial impact through several mitigation actions. On Thursday, Kenvue appointed Amit Banati as the company’s CFO, effective May 12, 2025. Mr.